Cardiol Therapeutics Inc. (CRDL)
Cardiol Therapeutics Statistics
Share Statistics
Cardiol Therapeutics has 82.63M shares outstanding. The number of shares has increased by 18.27% in one year.
| Shares Outstanding | 82.63M |
| Shares Change (YoY) | 18.27% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 10.88% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 3,309 |
| FTD / Avg. Volume | 1.45% |
Short Selling Information
The latest short interest is 2.04M, so 2.47% of the outstanding shares have been sold short.
| Short Interest | 2.04M |
| Short % of Shares Out | 2.47% |
| Short % of Float | 2.56% |
| Short Ratio (days to cover) | 10 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -2.85 |
| PS Ratio | 0 |
| Forward PS | 1.5 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cardiol Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.52 |
| Quick Ratio | 4.52 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,562,682.83 |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -43.94% in the last 52 weeks. The beta is 0.67, so Cardiol Therapeutics's price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | -43.94% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 57.58 |
| Average Volume (20 Days) | 228,224 |
Income Statement
| Revenue | n/a |
| Gross Profit | -248.35K |
| Operating Income | -29.79M |
| Net Income | -28.13M |
| EBITDA | -29.59M |
| EBIT | -29.79M |
| Earnings Per Share (EPS) | -0.44 |
Balance Sheet
The company has 30.58M in cash and 158.53K in debt, giving a net cash position of 30.42M.
| Cash & Cash Equivalents | 30.58M |
| Total Debt | 158.53K |
| Net Cash | 30.42M |
| Retained Earnings | -179.25M |
| Total Assets | 31.86M |
| Working Capital | 24.66M |
Cash Flow
In the last 12 months, operating cash flow was -25.06M and capital expenditures -21.29K, giving a free cash flow of -25.08M.
| Operating Cash Flow | -25.06M |
| Capital Expenditures | -21.29K |
| Free Cash Flow | -25.08M |
| FCF Per Share | 0 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRDL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CRDL is $9, which is 710.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $9 |
| Price Target Difference | 710.8% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -3.93 |
| Piotroski F-Score | 2 |